When should filgrastim be used post-chemotherapy?

When should filgrastim be used post-chemotherapy?

• A. 12 hours after
• B. 24 hours after
• C. 48 hours after
• D. 72 hours after

Answer: (B)

Filgrastim is a granulocyte colony-stimulating factor (G-CSF) that is used to stimulate the production of neutrophils in patients undergoing chemotherapy, which often leads to neutropenia (a reduction in the number of neutrophils). The timing of filgrastim administration post-chemotherapy is crucial for optimizing its effectiveness in reducing the risk of infection due to low neutrophil counts. The recommended timing for administering filgrastim is typically 24 hours after the completion of chemotherapy. This timing allows for the recovery of bone marrow function and aids in the mobilization of neutrophils at the point when they are most needed, helping to mitigate the risk of febrile neutropenia and other complications related to low white blood cell counts. Administering it too early (within 12 hours) could interfere with the chemotherapy's effects, while waiting too long (48 or 72 hours) may not be as effective in preventing the delayed onset of neutropenia that can occur following chemotherapy cycles. Therefore, the correct schedule is crucial for maximizing the benefit of filgrastim in patients recovering from chemotherapy.

Filgrastim is a granulocyte colony-stimulating factor (G-CSF) that is used to stimulate the production of neutrophils in patients undergoing chemotherapy, which often leads to neutropenia (a reduction in the number of neutrophils). The timing of filgrastim administration post-chemotherapy is crucial for optimizing its effectiveness in reducing the risk of infection due to low neutrophil counts.

The recommended timing for administering filgrastim is typically 24 hours after the completion of chemotherapy. This timing allows for the recovery of bone marrow function and aids in the mobilization of neutrophils at the point when they are most needed, helping to mitigate the risk of febrile neutropenia and other complications related to low white blood cell counts. Administering it too early (within 12 hours) could interfere with the chemotherapy's effects, while waiting too long (48 or 72 hours) may not be as effective in preventing the delayed onset of neutropenia that can occur following chemotherapy cycles.

Therefore, the correct schedule is crucial for maximizing the benefit of filgrastim in patients recovering from chemotherapy.